Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc. - Common Stock (NQ: FHTX )

6.130 -0.030 (-0.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Foghorn Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. 
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Foghorn Therapeutics: Q4 Earnings Insights
Via Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
What 5 Analyst Ratings Have To Say About Foghorn Therapeutics
Via Benzinga
Analyst Ratings for Foghorn Therapeutics
Via Benzinga
What 6 Analyst Ratings Have To Say About Foghorn Therapeutics
Via Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher
Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for clinical development. 
Via Benzinga
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market... 
Via Benzinga
Analyst Expectations for Foghorn Therapeutics's Future
Via Benzinga
Expert Ratings for Foghorn Therapeutics
Via Benzinga
Foghorn Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in  
Via Benzinga
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16.... 
Via Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
Via Benzinga
US Stocks Turn Lower; Nasdaq Dips 100 Points
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P... 
Via Benzinga
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
Via Benzinga
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS